Verified peer comparison

ABBV vs VRTX

AbbVie Inc. compared with Vertex Pharmaceuticals Incorporated. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

VRTX

Vertex Pharmaceuticals Incorporated

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABBV: Biotechnology

VRTX: Biotechnology

Upside lens

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

VRTX: ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients. CASGEVY and JOURNAVX adoption can establish meaningful franchises beyond cystic fibrosis. Povetacicept regulatory and late-stage progress can create a fourth major disease-area franchise.

Risk lens

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

VRTX: Cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition. Gene-editing and pain products face complex patient identification, delivery and reimbursement pathways. Late-stage failures or regulatory delays could materially reduce pipeline diversification value.